Bausch Health

The Company also announced that its Board of Directors has authorized a $50 million share repurchase program, with the primary objective of offsetting dilution associated with the anticipated vesting of management equity awards in 2027.

SEC original ↗Bausch Health — Earnings release (8-K exhibit)EX-99Oct 28, 2026

Our performance reflects disciplined execution across the portfolio, with healthy cash generation supporting more than $500 million of net debt reduction during the quarter.

SEC original ↗Bausch Health — Earnings release (8-K exhibit)EX-99Oct 28, 2026

Upon the successful completion of major refinancing initiatives in the prior twelve-month period, the Company materially improved its debt maturity profile.

SEC original ↗Bausch Health — Earnings release (8-K exhibit)EX-99Oct 28, 2026

Loss (gain) on extinguishment of debt The Company has excluded loss (gain) on extinguishment of debt as this represents a gain or loss from refinancing our existing debt and is not a reflection of our operations for the period.

SEC original ↗Bausch Health — Earnings release (8-K exhibit)EX-99Oct 28, 2026

Further, the amount and frequency of such amounts are not consistent and are significantly impacted by the timing and size of debt financing transactions and other factors in the debt market out of management s control.

SEC original ↗Bausch Health — Earnings release (8-K exhibit)EX-99Oct 28, 2026

Write down of financing fees In addition to excluding Loss (gain) on extinguishment of debt, the Company has excluded the impact of the write down of financing fees from Adjusted net income (non-GAAP).

SEC original ↗Bausch Health — Earnings release (8-K exhibit)EX-99Oct 28, 2026

We remain focused on operational excellence, sustainable growth, and long-term value creation, said Thomas J.

SEC original ↗Bausch Health — Earnings release (8-K exhibit)EX-99Oct 28, 2026

The Company remains focused on strengthening its balance sheet and delivering value to all stakeholders.

SEC original ↗Bausch Health — Earnings release (8-K exhibit)EX-99Oct 28, 2026

Focus on Strategic Priorities The Company exits the third quarter of 2026 with strong financial momentum, with revenue and earnings growth across multiple segments.

SEC original ↗Bausch Health — Earnings release (8-K exhibit)EX-99Oct 28, 2026

Upon the successful completion of major refinancing initiatives in the prior twelve-month period, the Company materially improved its debt maturity profile.

SEC original ↗Bausch Health — Earnings release (8-K exhibit)EX-99Oct 28, 2026

Adjusted EBITDA (non-GAAP) is Net income (loss) (its most directly comparable GAAP financial measure) adjusted for interest, income taxes, depreciation and amortization and the following items Restructuring, integration and transformation costs The Company has incurred restructuring costs as it implemented certain strategies, which involved, among other things, improvements to its infrastructure and operations, internal reorganizations and impacts from the divestiture of assets and businesses.

SEC original ↗Bausch Health — Earnings release (8-K exhibit)EX-99Oct 28, 2026

Bausch Health (excluding Bausch + Lomb) is raising its full year Revenue, Adjusted EBITDA 1 , and Adjusted Cash Flows from Operations 1 guidance, which includes the currently estimated impact of applicable tariffs for the calendar year as of the date of this release.

SEC original ↗Bausch Health — Earnings release (8-K exhibit)EX-99Oct 28, 2026

The rapid recent developments in the evolving landscape of tariffs and responses have resulted in uncertainty regarding these measures and the effects they may have.

SEC original ↗Bausch Health — Earnings release (8-K exhibit)EX-99Oct 28, 2026

We continue to assess the direct and indirect impacts on our businesses of such tariffs, including retaliatory tariffs and other trade protectionist measures as the situation develops, and there can be no assurance that such impacts will not be adverse.

SEC original ↗Bausch Health — Earnings release (8-K exhibit)EX-99Oct 28, 2026

Other adjustments The Company has excluded certain other amounts, including legal and other professional fees incurred in connection with legal and governmental proceedings, investigations and information requests regarding certain of our legacy distribution, marketing, pricing, disclosure and accounting practices, litigation and other matters, and net (gain) loss on sale of assets or other disposition of assets.

SEC original ↗Bausch Health — Earnings release (8-K exhibit)EX-99Oct 28, 2026

However, investors should understand that many of these costs could recur and that companies in our industry often face litigation.

SEC original ↗Bausch Health — Earnings release (8-K exhibit)EX-99Oct 28, 2026

(g) Represents the sole component of the non-GAAP adjustment of Litigation and other matters, net of insurance recoveries and restitutions (see Table 2).

SEC original ↗Bausch Health — Earnings release (8-K exhibit)EX-99Oct 28, 2026